Clinical Trials in the USA / NCT07794670
Recruiting
Phase 2
Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease
NCT07794670 · tracked via the Priya Life Science USA tracker
Condition(s) studied
Preclinical Alzheimer's Disease
Investigational drug(s) / intervention(s)
Obicetrapib 10 mg →Matching placebo tablets
Obicetrapib 10 mg: once daily 10 mg Obicetrapib tablet
Matching placebo tablets: matching placebo tablet
Study summary
A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease
Eligibility
Inclusion Criteria:
* participants with preclinical AD
Exclusion Criteria:
* APOE genotype not meeting protocol-defined eligibility criteria
Primary outcome measure(s)
- Change from Baseline to Week 52 in ptau 217 — Baseline, Week 52
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| K2 Medical Research | Nashville | Tennessee | Recruiting |
More NewAmsterdam Pharma trials in the USA
A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
Active, not recruiting
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
Active, not recruiting
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07794670 on ClinicalTrials.gov ↗ ← All trials in the USA